Bausch Health Files 8-K on Material Agreements
Ticker: BHC · Form: 8-K · Filed: Apr 15, 2025 · CIK: 885590
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
Related Tickers: BHC
TL;DR
Bausch Health (BHC) filed an 8-K on April 15th, detailing material agreements and changes affecting security holders.
AI Summary
Bausch Health Companies Inc. filed an 8-K on April 15, 2025, reporting on events that occurred on April 14, 2025. The filing indicates an entry into a material definitive agreement, material modifications to the rights of security holders, and includes Regulation FD disclosures and financial statements/exhibits. The company was formerly known as Valeant Pharmaceuticals International, Inc. and BIOVAIL Corp.
Why It Matters
This 8-K filing signals significant corporate actions or agreements by Bausch Health Companies Inc., potentially impacting its business operations, financial standing, or shareholder rights.
Risk Assessment
Risk Level: medium — 8-K filings often disclose material events that can significantly impact a company's stock price and future prospects.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- Valeant Pharmaceuticals International, Inc. (company) — Former Company Name
- BIOVAIL Corp (company) — Former Company Name
- April 14, 2025 (date) — Date of Earliest Event Reported
- April 15, 2025 (date) — Filing Date
FAQ
What specific material definitive agreement did Bausch Health Companies Inc. enter into on April 14, 2025?
The filing indicates an entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What are the material modifications to the rights of security holders mentioned in the filing?
The filing states there were material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
What is the significance of the Regulation FD Disclosure item in this 8-K?
The Regulation FD Disclosure item indicates that the company is providing information that could be considered material non-public information to the public, ensuring fair disclosure.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these documents is not detailed in the provided text.
When did Bausch Health Companies Inc. change its name from Valeant Pharmaceuticals International, Inc.?
Bausch Health Companies Inc. changed its name from Valeant Pharmaceuticals International, Inc. on September 28, 2010.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2025 regarding Bausch Health Companies Inc. (BHC).